Osteonectin (SPARC) as a Therapeutic Target for the treatment and Prevention of acute hepatic failure, Pharmaceutical composition, Genetic Construct, siRNA, Agent that Inhibits expression, use
ASOCIACIÓN CIVIL DE ESTUDIOS SUPERIORES;CONSEJO NACIONAL DE INVESTIGACIONES CIENTÍFICAS Y TÉCNICAS (CONICET);FUNDACIÓN INSTITUTO LELOIR
发明人:
GUILLERMO DANIEL MAZZOLINI,MARIA CATALINA ATORRASAGASTI,ESTANISLAO PEIXOTO,JORGE AQUINO,OSVALDO LUIS PODHJACER
申请号：
ARP140103325
公开号：
AR099641A1
申请日:
2014.09.05
申请国别(地区):
AR
年份:
2016
代理人:
摘要：
Identification of toxin secret protein in toxin toxin (oyster) The strategy addresses the treatment objectives for patients with acute liver failure or stroke hepatitis (SPARC) and helps to develop a strategy to protect the liver from damage.To a person who needs a substance that at least partially inhibits the expression of osteotoxin and / or interferes with its biological function. Requirement 1: methods to prevent or treat acute liver failure or acute liver damageIn this case, the method includes managing agents that at least partially inhibit the expression of osteotoxin and / or interfere with its biological function. Claim 2: method of claim 1, in which the preparation at least partially suppresses the performance of oysters, is a gene structure capable of expressing RNA antibody molecules complementary to oyster RNM. Claim 3: the method of claim 2, wherein the gene is constructed as a recombinant gland. Claim 4: claimed method 3,Where the recombinant gland is the vector adassparc. Claim 6: the method of claim 5, in which the gene construction is a compound ienvirtus. Claim 14: pharmaceutical ingredients used to prevent or treat acute liver failure or acute liver damage, including preparations that at least partially inhibit the expression of osteotoxin and / or interfere with its biological function. Claim 15: pharmaceutical ingredients in claim 14,Here, at least part of the preparations that inhibit the expression of oysters are a kind of gene structure, which can express an RNA antibacterial molecule, which is a supplement to the RNM of oysters. 215. Claim 23: the pharmaceutical composition of claim 14, wherein the agent interfering with the biological function of oyster is an antibody against oyster. Requirement 39: preparation at least partially inhibiting oyster performance and / or interfering with its biological function for preventionOr treatment of acute liver failure or acute liver injury. Claim 51: a gene structure capable of expressing RNA resist
